Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
8
P 221
8+ YEARS OF IMMUNOTHERAPY FOR METASTATIC ALVEOLAR SOFT PART SARCOMA
Favorite
A
P 400
A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Favorite
P 98
A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Favorite
P 46
A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Favorite
P 322
A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Favorite
P 362
A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Favorite
P 363
A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Favorite
P 285
A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Favorite
P 182
A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Favorite
P 252
A NOVEL MULTIDISCIPLINARY SURGICAL APPROACH TO PERIPHERAL NERVE SHEATH TUMORS AND SOFT TISSUE SARCOMAS.
Favorite
P 364
A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Favorite
P 47
A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Favorite
P 401
A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Favorite
P 402
A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Favorite
P 01
A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Favorite
P 02
A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Favorite
P 183
A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Favorite
P 365
A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Favorite
P 48
A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Favorite
P 184
A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Favorite
P 418
A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Favorite
P 49
A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Favorite
P 366
ABDOMINAL AORTA RESECTION EN-BLOC WITH PRIMARY RETROPERITONEAL SOFT-TISSUE SARCOMA AND BI-ILIAC GRAFT RECONSTRUCTION.
Favorite
P 29
ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Favorite
P 138
ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS
Favorite
P 121
ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Favorite
P 99
ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Favorite
P 122
ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Favorite
P 286
ADAMANTINOMA - LIKE EWING SARCOMA WITH ATYPICAL PRESENTATION AND FATAL OUTCOME IN 20-YEAR-OLD WOMAN - A CASE REPORT
Favorite
P 185
ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Favorite
P 100
ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 367
AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Favorite
P 368
AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Favorite
P 287
AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Favorite
P 323
AN IN-VITRO INVESTIGATION OF 5-AMINOLEVULINIC ACID MEDIATED PHOTODYNAMIC THERAPY IN SOFT-TISSUE SARCOMA
Favorite
P 101
AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Favorite
P 162
ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Favorite
P 102
ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Favorite
P 50
ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Favorite
P 186
ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Favorite
P 222
ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Favorite
P 288
ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Favorite
P 289
APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Favorite
P 290
ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Favorite
P 123
ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Favorite
P 51
ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA
Favorite
P 253
ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Favorite
P 124
ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Favorite
P 223
ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Favorite
P 392
ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES
Favorite
P 254
ATYPICAL FEMUR FRACTURE IN A TEENAGER ON CHRONIC IMATINIB THERAPY
Favorite
B
P 324
BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Favorite
P 369
BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Favorite
P 419
BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Favorite
P 346
BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Favorite
P 103
BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Favorite
P 187
BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Favorite
P 188
BURDENS OF A CAREGIVER TO SARCOMA PATIENT AND HOW TO REDUCE THEM
Favorite
C
P 255
CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Favorite
P 325
CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Favorite
P 347
CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Favorite
P 291
CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Favorite
P 03
CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Favorite
P 326
CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Favorite
P 420
CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Favorite
P 52
CEMENT-AUGMENTED INTERNAL FIXATION FOR TEMPORIZING BONE SARCOMAS OF THE HIP
Favorite
P 125
CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Favorite
P 139
CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Favorite
P 163
CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Favorite
P 421
CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Favorite
P 292
CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Favorite
P 327
CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Favorite
P 256
CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Favorite
P 53
CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Favorite
P 126
CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Favorite
P 54
CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Favorite
P 55
CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Favorite
P 56
CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Favorite
P 04
CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Favorite
P 293
CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Favorite
P 140
CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Favorite
P 104
CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Favorite
P 189
CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Favorite
P 30
CLINICAL BENEFIT OF PEGYLATED-LIPOSOMAL DOXORUBICIN IN THE MANAGEMENT DESMOID TYPE FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 164
CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
Favorite
P 31
CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 190
CLINICAL FEATURES ASSOCIATED WITH DIFFERENT HISTOLOGICAL SUBTYPES OF SARCOMA: A POPULATION-BASED STUDY OF 97062 CASES
Favorite
P 57
CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE
Favorite
P 105
CLINICAL OUTCOMES OF SUB-CENTIMETRIC LUNG NODULES IN PATIENTS WITH EXTREMITY OSTEOSARCOMA: A RETROSPECTIEV COHORT STUDY
Favorite
P 191
CLINICOPATHOLOGICAL CHARACTERISTICS OF ANGIOSARCOMA AND THE RISK OF MULTIPLE PRIMARY MALIGNANCIES
Favorite
P 58
COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Favorite
P 257
COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Favorite
P 294
COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Favorite
P 258
COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Favorite
P 422
COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Favorite
P 423
COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Favorite
P 165
COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Favorite
P 224
COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Favorite
P 141
COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Favorite
P 59
COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Favorite
P 259
COMPRESSION OF INTERCALARY ALLOGRAFTS WITH MAGNETIC LENGTHENING NAILS, MID-TERM RESULTS WITH A COMPARISON OF TECHNIQUES
Favorite
P 142
CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Favorite
P 424
CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Favorite
P 32
CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Favorite
P 192
CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Favorite
D
P 166
D842V - A TALE OF TWO STAGES: COMPARATIVE ANALYSIS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN GIST PATIENTS WITH PDGFRA D842V MUTATIONS
Favorite
P 403
DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Favorite
P 127
DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Favorite
P 295
DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Favorite
P 167
DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Favorite
P 370
DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Favorite
P 106
DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Favorite
P 33
DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Favorite
P 34
DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Favorite
P 328
DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Favorite
P 225
DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Favorite
P 329
DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Favorite
P 05
DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Favorite
P 60
DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Favorite
P 06
DIFFICULTIES IN ASSESSING THE PROGNOSTIC SIGNIFICANCE OF A NOVEL BIOMARKER IN THE CONTEXT OF A TISSUE BANKING STUDY
Favorite
P 07
DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Favorite
P 296
DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Favorite
P 193
DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Favorite
P 61
DOES CLINICAL PROGRESSION PORTEND POOR ONCOLOGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY
Favorite
P 62
DOES LIQUID NITROGEN RECYCLED AUTOGRAFT FOR TREATMENT OF BONE SARCOMA IMPACT LOCAL RECURRENCE RATE? A SYSTEMATIC REVIEW
Favorite
P 107
DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Favorite
P 63
DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Favorite
P 128
DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Favorite
E
P 143
EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Favorite
P 226
EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Favorite
P 35
EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Favorite
P 36
EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Favorite
P 194
EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Favorite
P 393
EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Favorite
P 227
EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE
Favorite
P 168
EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Favorite
P 330
EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Favorite
P 331
EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Favorite
P 371
ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Favorite
P 129
ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Favorite
P 08
ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Favorite
P 260
EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Favorite
P 404
ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Favorite
P 195
ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Favorite
P 332
ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Favorite
P 64
ENTINOSTAT ENHANCES PRO-INFLAMMATORY CHEMOKINE PRODUCTION AND INCREASES RADIATION-INDUCED APOPTOSIS IN EWING SARCOMA
Favorite
P 65
EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Favorite
P 372
ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Favorite
P 297
ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Favorite
P 196
ESTABLISHING THE BONE CANCER RESEARCH TRUST'S PATIENT & PUBLIC INVOLVEMENT PANEL
Favorite
P 333
ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 348
EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Favorite
P 261
EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Favorite
P 373
EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Favorite
P 197
EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
Favorite
P 262
EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Favorite
P 298
EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Favorite
P 66
EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Favorite
P 334
EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Favorite
P 144
EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Favorite
P 145
EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Favorite
P 425
EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Favorite
P 146
EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Favorite
P 228
EXPLORING THE LINK BETWEEN TUMOUR INFILTRATING IMMUNE CELLS AND PATIENT OUTCOME IN SOFT TISSUE SARCOMA: A CLOSER LOOK AT MACROPHAGES
Favorite
P 299
EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Favorite
P 229
EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Favorite
P 67
EXTERMITY SOFT TISSUE SARCOMA -RETROSPECTIVE ANALYSIS OF 21YEARS EXPERIENCE IN A TERTITARY CARE CENTRE.
Favorite
F
P 374
FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Favorite
P 198
FACTORS INFLUENCING TIME TO TREATMENT INITIATION IN PROMARY EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS
Favorite
P 68
FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Favorite
P 09
FERROPTOSIS INDUCTION: A BIOCHEMICAL VULNERABILITY OF SOFT TISSUE SARCOMAS
Favorite
P 199
FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Favorite
P 108
FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Favorite
P 335
FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Favorite
P 200
FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Favorite
P 169
FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Favorite
P 375
FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Favorite
G
P 170
GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Favorite
P 300
GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Favorite
P 171
GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Favorite
P 426
GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Favorite
P 10
GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Favorite
P 11
GENETIC AND EPIGENETIC CHARACTERIZATION OF SARCOMA STEM CELLS ACROSS SUBTYPES IDENTIFIES EZH2 AS A THERAPEUTIC TARGET
Favorite
P 12
GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Favorite
P 301
GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
Favorite
P 13
GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Favorite
P 172
GIST WITH ATYPICAL MORPHOLOGY INITIALLY MISDIAGNOSED-THE IMPORTANCE OF BROAD IMMUNOCHEMISTRY-A CASE REPORT
Favorite
P 201
GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Favorite
H
P 69
H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Favorite
P 14
HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS
Favorite
P 37
HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Favorite
P 130
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Favorite
P 263
HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Favorite
P 302
HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Favorite
P 131
HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Favorite
P 230
HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Favorite
P 15
HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 16
HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Favorite
I
P 17
IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Favorite
P 231
IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Favorite
P 70
IDENTIFICATION OF NOVEL PROTEIN VARIANTS IN OSTEOSARCOMA TUMORS THROUGH LONG-READ RNA SEQUENCING
Favorite
P 394
IDENTIFYING THE INTERACTOME OF THE ONCOGENIC FUSIONS OF SARCOMAS TO REVEAL NOVEL THERAPEUTIC TARGETS
Favorite
P 232
IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Favorite
P 233
IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Favorite
P 18
IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Favorite
P 234
IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Favorite
P 202
IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Favorite
P 203
IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Favorite
P 376
IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Favorite
P 204
IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Favorite
P 336
IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Favorite
P 173
IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Favorite
P 377
INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Favorite
P 174
INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Favorite
P 235
INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Favorite
P 378
INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Favorite
P 395
INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS
Favorite
P 109
INTEGRATED TRANSCRIPTOMIC ANALYSIS OF CIC::DUX4 FUSION SARCOMAS REVEALS ELEVATED PROLIFERATION SIGNALING AND IMPLICATES DNA REPAIR GENE POLE
Favorite
P 236
INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Favorite
P 110
INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Favorite
P 111
INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Favorite
P 237
INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Favorite
P 264
INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Favorite
P 238
INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Favorite
P 239
INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Favorite
P 240
INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Favorite
P 147
INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Favorite
P 303
INVESTIGATING THE THERAPEUTIC POTENTIAL OF TRIPTOLIDE PRODRUG, MINNELIDE, AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Favorite
P 19
INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Favorite
P 265
IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Favorite
P 148
ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Favorite
K
P 379
KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR
Favorite
P 175
KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Favorite
L
P 149
LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Favorite
P 20
LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Favorite
P 71
LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Favorite
P 241
LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Favorite
P 405
LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Favorite
P 72
LIVE-CELL TISSUE MODELS REVEAL SOURCES OF DYNAMIC HETEROGENEITY IN THE OSTEOSARCOMA METASTATIC NICHE
Favorite
P 304
LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Favorite
P 38
LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Favorite
P 305
LOCAL THERAPY APPROACHES IN RELAPSED PEDIATRIC SOFT TISSUE SARCOMA AND EWING SARCOMA PATIENTS: A SINGLE INSTITUTION SERIES
Favorite
P 266
LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Favorite
P 306
LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Favorite
P 73
LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Favorite
P 406
LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION
Favorite
P 407
LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Favorite
P 396
LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Favorite
P 267
LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION
Favorite
P 349
LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Favorite
P 176
LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Favorite
P 268
LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Favorite
P 21
LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
Favorite
P 269
LYMPHOEDEMA FOLLOWING LIMB SALVAGE SURGERY FOR EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS OF 282 PATIENTS
Favorite
M
P 112
MACHINE LEARNING ANALYSIS TO DEFINE CELL LINEAGE IN LEIOMYOSARCOMA
Favorite
P 74
MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Favorite
P 22
MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Favorite
P 75
METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Favorite
P 23
METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Favorite
P 113
METASTATIC EWING'S TRAIL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES (METTSEO)
Favorite
P 114
METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Favorite
P 242
MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Favorite
P 150
MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Favorite
P 151
MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS
Favorite
P 76
MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Favorite
P 350
MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Favorite
P 397
MTOR ACTIVITY: A BIOMARKER FOR CHEMO- AND IMMUNOTHERAPY RESPONSE AND OUTCOMES IN SARCOMAS
Favorite
P 380
MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Favorite
P 205
MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Favorite
P 427
MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Favorite
P 77
MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Favorite
P 243
MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Favorite
N
P 24
NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Favorite
P 78
NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Favorite
P 152
NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Favorite
P 79
NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Favorite
O
P 428
OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Favorite
P 381
OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Favorite
P 337
OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Favorite
P 270
OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Favorite
P 408
OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Favorite
P 351
OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Favorite
P 80
OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Favorite
P 81
OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Favorite
P 271
OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Favorite
P 272
OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Favorite
P 307
OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Favorite
P 352
OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Favorite
P
P 308
PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Favorite
P 382
PARAGANGLIOMA AND CONGENITAL HEART DISEASE - A RARE CASE REPORT
Favorite
P 132
PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Favorite
P 39
PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE
Favorite
P 206
PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Favorite
P 207
PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Favorite
P 429
PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Favorite
P 153
PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Favorite
P 40
PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Favorite
P 41
PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT
Favorite
P 409
PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Favorite
P 410
PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Favorite
P 309
PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Favorite
P 82
PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Favorite
P 338
PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Favorite
P 177
PREDICTING THE IMATINIB RESPONSE OF PDGFRA EXON 18-MUTANT GASTROINTESTINAL STROMAL TUMOR USING IN VITRO MODELS
Favorite
P 353
PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Favorite
P 83
PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Favorite
P 178
PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Favorite
P 244
PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Favorite
P 398
PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Favorite
P 245
PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Favorite
P 154
PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Favorite
P 383
PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Favorite
P 179
PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Favorite
P 155
PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Favorite
P 273
PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS
Favorite
P 25
PRIMARY TREATED VERSUS REFERRED TRUNK AND EXTREMITIES SOFT TISSUE SARCOMAS: ANALYSIS OF TREATMENT IMPACT IN A SPECIALIZED CENTER IN ARGENTINA.
Favorite
P 156
PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Favorite
P 84
PROGNOSTIC IMPLICATIONS OF PATHOLOGICAL FRACTURES IN EXTREMITY OSTEOSARCOMA: A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES AND LIMB-SALVAGE FEASIBILITY
Favorite
P 310
PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS
Favorite
P 411
PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Favorite
P 115
PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Favorite
P 354
PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Favorite
P 355
PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Favorite
P 274
PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Favorite
P 208
PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Favorite
P 85
PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Favorite
Q
P 311
QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Favorite
P 430
QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Favorite
P 116
QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Favorite
R
P 209
RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Favorite
P 356
RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Favorite
P 357
RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Favorite
P 210
RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Favorite
P 358
RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Favorite
P 42
RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Favorite
P 359
RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Favorite
P 312
RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD
Favorite
P 157
REAL WORLD CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS
Favorite
P 384
REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Favorite
P 133
REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Favorite
P 134
REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Favorite
P 431
REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Favorite
P 211
REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
Favorite
P 275
RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Favorite
P 276
RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE
Favorite
P 158
RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
Favorite
P 212
REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Favorite
P 213
REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Favorite
P 313
RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Favorite
P 214
REPRESENTATION OF CHILDREN AND OLDER ADULTS IN SARCOMA CLINICAL TRIALS SINCE THE INCLUSION ACROSS THE LIFESPAN POLICY
Favorite
P 215
REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN SARCOMA CLINICAL TRIALS
Favorite
P 86
RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Favorite
P 314
RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Favorite
P 277
REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
Favorite
P 278
ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Favorite
S
P 87
SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Favorite
P 43
SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Favorite
P 315
SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Favorite
P 412
SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Favorite
P 26
SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Favorite
P 216
SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Favorite
P 217
SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Favorite
P 339
SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Favorite
P 316
SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Favorite
P 218
SEX DIFFERENCES IN THE ASSOCIATION OF ALCOHOL INTAKE WITH THE RISK OF SOFT-TISSUE SARCOMA: A NATIONWIDE POPULATION-BASED RETROSPECTIVE COHORT STUDY
Favorite
P 279
SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Favorite
P 399
SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Favorite
P 385
SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM
Favorite
P 317
SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Favorite
P 219
SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Favorite
P 386
SOLITARY FIBROUS TUMOUR: A DANISH SAMPLE FROM 2013 – 2018
Favorite
P 88
SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Favorite
P 220
SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Favorite
P 387
SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Favorite
P 27
SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Favorite
P 280
SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Favorite
P 135
SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Favorite
P 413
SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Favorite
P 318
SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Favorite
T
P 89
TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Favorite
P 90
TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Favorite
P 136
TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Favorite
P 137
TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Favorite
P 414
TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Favorite
P 340
THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Favorite
P 91
THE EFFECT OF CHEMOTHERAPY AND SURGERY TIMING ON MORTALITY IN THE TREATMENT OF UPPER AND LOWER EXTREMITY OSTEOSARCOMA: A DATABASE STUDY
Favorite
P 341
THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Favorite
P 246
THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Favorite
P 92
THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Favorite
P 28
THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Favorite
P 93
THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Favorite
P 247
THE REAL-WORLD EFFICACY OF IMMUNE CHECKPOINT INHIBITORS WITH CONCURRENT RADIATION OR SURGERY IN MULTIMODAL TREATMENT OF SOFT TISSUE SARCOMAS: A RETROSPECTIVE STUDY
Favorite
P 388
THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Favorite
P 94
THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA
Favorite
P 342
THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Favorite
P 389
THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Favorite
P 432
THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Favorite
P 319
THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Favorite
P 95
THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Favorite
P 117
THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Favorite
P 281
THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Favorite
P 343
TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Favorite
P 248
TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Favorite
P 415
TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Favorite
P 96
TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Favorite
P 344
TRANSCRIPTOMIC ANALYSIS OF DESMOID TUMOR RESPONSE TO NIROGACESTAT: NOVEL MECHANISMS OF RESISTANCE?
Favorite
P 345
TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Favorite
P 97
TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Favorite
P 360
TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Favorite
P 416
TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Favorite
P 249
TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Favorite
P 433
TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Favorite
P 44
TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Favorite
P 180
TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Favorite
U
P 282
UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN
Favorite
P 118
UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Favorite
P 250
UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Favorite
P 251
UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Favorite
P 181
UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Favorite
P 119
UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 283
USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Favorite
P 120
USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Favorite
P 159
USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Favorite
P 160
UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Favorite
P 161
UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Favorite
P 434
UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Favorite
P 45
UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Favorite
V
P 390
VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Favorite
P 391
VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Favorite
P 417
VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Favorite
W
P 320
WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Favorite
P 321
WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Favorite
P 361
WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Favorite
P 284
WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Favorite
